CVSI CV Sciences, Inc.

OTC Pharmaceutical Preparations DE CIK: 0001510964
AI RATING
STRONG_SELL
85% Confidence

Investment Thesis

CV Sciences demonstrates severe operational distress with persistent negative profitability across all metrics and deteriorating cash flow generation. The company is consuming cash through operations while maintaining minimal liquidity reserves and substantial debt, creating an unsustainable financial position that threatens long-term viability.

Strengths

  • + Reasonable gross margin of 48.5% indicates underlying product economics are viable at the production level
  • + Current ratio of 1.06x provides minimal short-term liquidity cushion
  • + Debt-to-equity ratio of 0.83x is moderate relative to total capitalization

Risks

  • ! Negative operating cash flow of -53.0K combined with -153.0K free cash flow indicates the company is burning through capital reserves and cannot sustain operations from internal cash generation
  • ! Negative net income of -752.0K with net margin of -7.2% and ROE of -48.9% demonstrate the company is not generating shareholder value and is destroying equity
  • ! Quick ratio of 0.21x and cash position of only 381.0K relative to 5.5M in liabilities creates severe liquidity risk; company has less than 2 months of cash at current burn rate
  • ! Revenue flat to declining (-1.9% YoY) while losing money indicates inability to achieve profitable scale or cost control
  • ! No insider buying activity in last 90 days suggests management lacks confidence in near-term prospects

Key Metrics to Watch

Financial Metrics

Revenue
10.5M
Net Income
-752.0K
EPS (Diluted)
$0.00
Free Cash Flow
-153.0K
Total Assets
7.0M
Cash
381.0K

Profitability Ratios

Gross Margin 48.5%
Operating Margin -3.8%
Net Margin -7.2%
ROE -48.9%
ROA -10.8%
FCF Margin -1.5%

Balance Sheet & Liquidity

Current Ratio
1.06x
Quick Ratio
0.21x
Debt/Equity
0.83x
Debt/Assets
78.0%
Interest Coverage
-0.66x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-23T06:38:11.498503 | Data as of: 2025-09-30 | Powered by Claude AI